Related Experiment Video
Updated: Mar 29, 2026
04:09
Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
Published on: December 13, 2024
1.5K
Alginate-based bipolymeric-nanobioceramic composite matrices for sustained drug release
M Saquib Hasnain1, Amit Kumar Nayak2, Mukul Singh3
1Department of Pharmacy, Shri Venkateshwara University, NH-24, Rajabpur, Gajraula, Amroha 244236, UP, India.
International Journal of Biological Macromolecules
|November 27, 2015
Summary
New alginate-poly (vinyl pyrrolidone) composite beads incorporating nano-hydroxyapatite [nHAp] offer sustained drug release. These nanobioceramic matrices show high entrapment efficiency and follow a non-Fickian release mechanism over 8 hours.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Alginate and poly (vinyl pyrrolidone) (PVP) are widely used biocompatible polymers.
- Nano-hydroxyapatite (nHAp) possesses excellent biocompatibility and osteoconductivity.
- Sustained drug delivery systems are crucial for improving therapeutic efficacy and patient compliance.
Purpose of the Study:
- To develop novel alginate-based bipolymeric-nanobioceramic composite matrices for sustained drug release.
- To investigate the characteristics and drug release kinetics of these composite beads.
- To evaluate the potential of nHAp-alginate-PVP blends as drug delivery vehicles.
Main Methods:
- Synthesis of nano-hydroxyapatite (nHAp) powders via precipitation.
- Preparation of nHAp-alginate-PVP composite beads using ionotropic gelation.
- Characterization of beads using Scanning Electron Microscopy (SEM) and Fourier Transform-Infrared (FTIR) spectroscopy.
- Assessment of drug entrapment efficiency and drug release profiles over 8 hours.
Main Results:
- Synthesized nHAp powders had an average particle size of 19.04 nm.
- nHAp-alginate-PVP beads exhibited high drug entrapment efficiency (65.82% to 94.45%).
- Beads showed sustained drug release following the Koresmeyer-Peppas model (R²=0.9908-0.9978) with anomalous transport mechanism (n=0.73-0.84).
Conclusions:
- Alginate-based bipolymeric-nanobioceramic composite matrices are effective for sustained drug delivery.
- The incorporation of nHAp enhances the properties of alginate-PVP beads for drug entrapment and release.
- These composite beads demonstrate potential as advanced drug delivery systems with controlled release kinetics.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
89
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
89
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
109
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
308
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
308
01:11Oral Drug Delivery Systems: Delayed-Release Systems
144
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
144
01:26Oral Drug Delivery Systems: Continuous-Release Systems
212
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
212
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
102
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
102